Search results
Results from the WOW.Com Content Network
Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [7] [10] It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. [7]
Description - includes the proprietary name (if any), nonproprietary name, dosage form(s), qualitative and/or quantitative ingredient information, the pharmacologic or therapeutic class of the drug, chemical name and structural formula of the drug, and if appropriate, other important chemical or physical information, such as physical constants ...
More data about the cardiac risk from escitalopram can be found in a large observational study from Sweden that took note of all the medications used by all the patients presenting with TdP, and found the incidence of TdP in escitalopram users to be only 0.7 cases of TdP for every 100,000 patients who took the drug (ages 18-64), and only 4.1 ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The compilation is financially supported in part by pharmaceutical manufacturing corporations which create drugs listed within its pages. The 71st Edition, published in 2017, was the final hardcover edition. It weighed in at 4.6 pounds (2.1 kg) and contained information on over 1,000 drugs. [1]
The merged company bought J. B. Lippincott & Co. of Philadelphia in 1990; it merged Lippincott with the Raven Press to form Lippincott-Raven in 1995. [2] In 1997 and 1998, Wolters Kluwer acquired Thomson Science (owner of the Current Opinion medical journals), and Plenum and merged the medical publications of each with Lippincott-Raven. [3]
UpToDate's articles are anonymously peer-reviewed and it mandates the disclosure of conflicts of interest by the authors of its articles. In 2014, an article was published in the Journal of Medical Ethics which scrutinised six articles on UpToDate and DynaMed focusing on conditions where the best means of management is contested, or which are treated mostly by branded drugs.
Flutamide and nilutamide are first-generation NSAAs, similarly to bicalutamide, and all three drugs possess the same core mechanism of action of being selective AR antagonists. [22] However, bicalutamide is the most potent of the three, with the highest affinity for the AR [ 23 ] [ 24 ] and the longest elimination half-life, [ 10 ] and is the ...